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Abstract
Background: Hepcidin has an important role in iron metabolism. We investigated whether
hepcidin was involved in renal cell carcinoma (RCC).
Methods: We measured serum hepcidin-25 levels in 32 patients by liquid chromatograpy (LC)-
mass spectrometry (MS)/MS, and assessed hepcidin mRNA expression in paired tumor and non-
tumor tissue samples from the surgical specimens of 53 consecutive patients with RCC by real-time
reverse transcription polymerase chain reaction.
Results:  The serum hepcidin-25 level was higher in patients with metastatic RCC than
nonmetastatic RCC (P < 0.0001), and was positively correlated with the serum interleukin-6 and
C-reactive protein levels (P < 0.001). Expression of hepcidin mRNA was lower in tumor tissues
than in non-tumor tissues (P < 0.0001). The serum hepcidin-25 level was not correlated with the
expression of hepcidin mRNA in the corresponding tumor tissue specimens from 32 patients.
Hepcidin mRNA expression in tumor tissue was correlated with metastatic potential, but not with
histological differentiation or tumor stage. Kaplan-Meier analysis showed that over expression of
hepcidin mRNA was related to shorter overall survival in RCC patients. Univariate analysis (Cox
proportional hazards model) showed that the hepcidin mRNA level was an independent prognostic
factor for overall survival.
Conclusion: Our findings suggest that a high serum hepcidin-25 level may indicate the progression
of RCC, and that upregulation of hepcidin mRNA expression in tumor tissue may be related to
increased metastatic potential.
Background
Renal cell carcinoma (RCC) is the most common malig-
nant tumor of the kidneys and the third most common
malignancy in the urological field. More than 50% of all
RCCs are found incidentally, which results in a high per-
centage of patients with metastasis at the time of diagnosis
[1]. In patients with disseminated RCC, conventional
chemotherapy, radiotherapy, and immunotherapy have
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all been tried with limited efficacy [1-4]. Thus, more effec-
tive therapy is urgently needed to improve the outcome
for patients with advanced RCC. Better understanding of
the biology and genetics of RCC have shed light on possi-
ble targeted approaches to metastatic disease [5]. The
pathway involving the Hipple-Lindau (VHL) tumor sup-
pressor gene, hypoxia-inducible factor-1 (HIF-1) alpha,
and vascular endothelial growth factor (VEGF) is impor-
tant for the growth of clear cell RCC, and targeting this
pathway is a novel approach to the treatment of metastatic
RCC.
Iron is required as a cofactor for the catalytic activity of
HIF prolyl hydroxylases (HPHs) [6]. Iron is a pivotal
nutrient for cell growth and cell cycle regulation, so iron
chelators may be useful for the treatment of cancer [7]. It
has been reported that iron is more abundant in RCCs
than in the surrounding non-tumor tissues [8]. Therefore,
it is of interest to investigate the factors that modulate iron
metabolism in RCC. Hepcidin is a pivotal regulator of
iron metabolism because it controls the efflux of iron
from enterocytes, hepatocytes, and macrophages by inter-
nalization and degradation of the iron exporter (ferropor-
tin), and also regulates the plasma iron level [9,10].
Therefore, the role of hepcidin in human cancer deserves
to be studied. While there have been a few reports about
the role of hepcidin in some cancers [11,12], little is
known about its influence on RCC. In the present study,
we examined serum hepcidin-25 levels by liquid chroma-
tograpy (LC)-mass spectrometry (MS)/MS and compared
hepcidin mRNA expression between RCC tissues and
non-neoplastic tissues from the same resected specimens
by real-time reverse transcription-polymerase chain reac-
tion (RT-PCR). The relationship between the serum level
of hepcidin-25 and hepcidin mRNA expression or the
clinicopathologic features of RCC patients was also exam-
ined. Furthermore, we assessed whether hepcidin could
be used to predict the prognosis of RCC patients. Such
information might lead to with regard to the role of hep-
cidin in RCC.
Methods
Patients and tissue specimens
We studied 53 consecutive Japanese patients (37 men and
16 women) aged 35 to 77 years (mean age: 62.9 years),
who were diagnosed as having clear cell RCC from 2002
to 2007. All patients routinely underwent imaging studies
(CT and/or MRI) for preoperative staging prior to radical
nephrectomy. The postoperative follow-up period ranged
from 2 to 84 months (median: 29 months). Patients
underwent surgery before receiving any other therapy.
In every patient, three different tumor sites and various
parts of the non-neoplastic kidney were harvested for this
study. The resected tissues were stored at -80°C, as
described previously [13-15]. The tumor grade and clini-
cal stage were determined according to the Fuhrman grad-
ing system and the TNM classification, respectively
[16,17]. This study was conducted in accordance with the
Declaration of Helsinki and institutional review board
approval was obtained. Each patient signed a consent
form that had been approved by the Committee on
Human Rights in Research of our institution.
Postoperative immunotherapy with IFN-α was usually
administered to patients with extra-renal involvement.
These patients received 3, 5, or 6 million units of natural
human IFN-α intravenously or intramuscularly two or
three times a week for 12 weeks to 6 months, or until
tumor progression occurred. The dose of IFN-α was
decreased if grade 3/4 toxicity occurred.
Measurement of serum hepcidin-25
The serum level of hepcidin-25 was measured in preoper-
ative blood samples obtained from 32 patients by LC-MS/
MS at Medical Care Proteomics Biotechnology Co., Ltd.
(Ishikawa, Japan), as described previously [18]. We com-
pared the serum hepcidin-25 level with hepcidin mRNA
expression in the 32 corresponding tumors, and also with
the serum levels of interleukin (IL)-6 (mean = 1.77 pg/ml,
n = 32, range: 0.447–9.96 pg/ml, R&D System Co. Ltd.)
and C-reactive protein (CRP) (normal < 0.3 mg/dl) in the
same 32 patients.
Real-time RT-PCR assay
Total RNA was purified from all 53 sets of tumor and non-
tumor tissue samples with an RNA preparation kit ("High
Pure RNA Kit"; Roche Diagnostic Ltd., Germany), and was
used as the template for cDNA synthesis. A 100 μL reac-
tion mixture containing 1 mg of random hexamers and
100 units of MMLV-reverse transcriptase was incubated at
25°C for 10 min, at 42°C for 30 min, and then at 99°C
for 5 min. The hepcidin gene expression profile was ana-
lyzed with an ABI PRISM 7700 Sequence Detection Sys-
tem (Applied Biosystems, Foster City, CA) using the SYBR
Green method. The following primers were employed to
amplify the indicated genes in the primary tumors after
confirming their specificity: hepcidin, sense; 5'-TTC-
CCCATCTGCATTTTCTG-3', anti-sense; 5'-TCTACGTCTT-
GCAGCACATCC-3'; b2-microglobulin, sense; 5'-
ACCCCCACTGAAAAAGATGA-3', anti-sense; 5'-ATCT-
TCAAACCTCCATGATG. Real-time RT-PCR was per-
formed in a 25 μL reaction mixture containing 20 ng of
sample cDNA, 100 nM sense primer, 100 nM anti-sense
primer, and 12.5 μL of SYBR Green PCR Master Mix
(Applied Biosystems). PCR was carried out by performing
45 cycles of hearting at 95°C for 15 sec and 60°C for 1
min. A standard curve for each mRNA was generated byBMC Cancer 2009, 9:270 http://www.biomedcentral.com/1471-2407/9/270
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using five-fold dilutions of a control RNA sample (25×,
5×, 1×, 0.2×, 0.04×). The level of expression of the target
gene mRNA was calculated as a ratio to that of b2-
microglobulin [14,15]. The mean value obtained by real-
time RT-PCR of three tissue samples was used for analysis,
as described previously [14,15].
Statistical analysis
The results of LC-MS/MS and real-time RT-PCR were ana-
lyzed by using the Mann-Whitney U test to compare two
groups and the Kruskal-Wallis test to compare three
groups, as described previously [13-15]. Hepcidin mRNA
expression, tumor grade, and tumor stage were assessed
for their impact on survival by Cox proportional hazards
analysis using univariate and multivariate models. The
Kaplan-Meier method was employed to estimate survival,
and differences were assessed by the log-rank test. A P
value of less than 0.05 was considered significant. Data
were analyzed with commercially available software.
Results
Serum hepcidin-25 level and tumor characteristics
There was no relationship between the serum hepcidin-25
level and the histological grade of RCC (mean ± S.D.,
grade 1, 17.02 ± 10.32; grade 2, 43.37 ± 40.04; grade 3,
35.58 ± 37.78, P = 0.1492, Figure 1A), or the tumor stage
(pT1–2, 26.21 ± 14.58; pT3–4, 50.75 ± 50.04, P = 0.0719,
Figure 1B). However, serum hepcidin-25 was associated
with metastasis (M0, 21.05 ± 12.42; M1, 73.14 ± 47.13, P
< 0.0001, Figure 1C). The serum IL-6 level was also corre-
lated with metastasis (M1, 19.41 ± 23.79; M0, 4.62 ± 6.19,
P = 0.0095), and it increased along with a higher tumor
grade (grade 1, 3.82 ± 2.21; grade 2, 9.74 ± 4.41; grade 3,
12.08 ± 3.57, P = 0.0836) and higher stage (pT1–2, 4.88 ±
6.63; pT3–4, 14.54 ± 20.99, P = 0.0926). A higher serum
CRP level was associated with poorly differentiated RCC
(grade 1, 0.10 ± 0.01; grade 2, 1.32 ± 2.33; grade 3, 2.56 ±
2.59, P = 0.0036), local invasion (pT1–2, 0.43 ± 0.90;
pT3–4, 2.52 ± 2.86, P = 0.0014), and metastatic disease
(M1, 3.45 ± 3.15; M0, 0.52 ± 0.92, P = 0.0004). The serum
hepcidin-25 level was positively correlated with the serum
levels of IL-6 and CRP (r2 = 0.664, P = 0.0003, and r2 =
0.724, P = 0.0002, respectively, Figure 2A,B). There was no
correlation between IL-6 and CRP levels (r2 = 0.704, P =
0.3471, Figure 2C). The serum hepcidin-25 level was not
correlated with the expression of hepcidin mRNA in the
corresponding tumor tissue samples from 32 patients
(data not shown).
Hepcidin mRNA expression and pathologic characteristics
Hepcidin mRNA was detected in both the tumors and in
non-tumorous kidney tissues, (mean ± S.D. 30.77 ±
100.51 and 456.83 ± 1280.80, respectively, P < 0.0001,
Figure 3A). The level of hepcidin mRNA expression in
RCC was not related to the tumor grade (mean ± S.D.
grade 1, 8.34 ± 8.66; grade 2, 16.36 ± 18.96; grade 3,
19.79 ± 23.12, P = 0.4249, Figure 3B) or the tumor stage
(pT1–2, 14.88 ± 19.15; pT3–4, 18.56 ± 20.13, P = 0.4348,
Figure 3C). However, hepcidin mRNA expression was
higher in the patients with metastasis (M1) compared to
those with tumors confined to the kidney (M0) (11.76 ±
13.23 vs. 30.44 ± 27.58, P = 0.0225; Figure 3D).
Hepcidin mRNA expression and survival
The median level of hepcidin mRNA expression in tumor
tissue was 7.83. Patients were divided into two groups
(high and low hepcidin expression) based upon whether
their hepcidin mRNA level was above or below this
median value. Kaplan-Meier analysis of patients with low
or high hepcidin mRNA expression suggested that higher
expression by RCC was significantly related to shorter
overall survival (P = 0.0221; Figure 4A). Univariate analy-
sis according to the Cox proportional hazards model
showed that overall survival was significantly influenced
by Karnofsky performance status, tumor grade, stage,
metastasis, and hepcidin mRNA expression (Table 1).
According to multivariate analysis, the performance status
and the tumor grade were independent prognostic factors
(Table 1). Patients without distant metastasis at the time
of nephrectomy (M0; n = 35) were also divided into
groups with hepcidin mRNA levels above or below the
median value of 6.08. In these patients with localized
tumors, Kaplan-Meier analysis showed that higher hepci-
din mRNA expression had no influence on disease-free
survival (Figure 4B).
Discussion
There were three main findings of this study. First, the
serum hepcidin-25 level was higher in patients with
metaststic RCC than in those without metastatic tumors.
Second, expression of hepcidin mRNA was increased in
metastatic RCCs compared with non-metastatic RCCs.
Third, although the follow-up period was too short to
draw definite conclusions about the relationship between
survival and hepcidin mRNA expression, higher tumor
expression of hepacidin mRNA was related to unfavorable
overall survival in our RCC patients.
Hepcidin is upregulated in response to an increase of
body iron stores or the onset of infection and is downreg-
ulated by anemia or hypoxia, while it is also an acute
phase reactant induced by inflammation that shows anti-
microbial activity [9,10]. It has been reported that induc-
tion of hepcidin is stimulated by IL-6 [19]. The circulating
level of CRP is associated with the stage and outcome of
RCC [20-23]. Although our data showed no positive cor-
relation between serum IL-6 and CRP levels, elevation of
the CRP level is primarily determined by an increase of cir-
culating IL-6 [24], and the IL-6 level is correlated with the
serum CRP level as well as with tumor histological gradeBMC Cancer 2009, 9:270 http://www.biomedcentral.com/1471-2407/9/270
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Serum hepcidin-25 concentration in the patients with renal cancers Figure 1
Serum hepcidin-25 concentration in the patients with renal cancers. A; In Grade 1 to 3 tumors. B; In pT1–2 and 
pT3–4 tumors. C: In metastasis (+ : 1) and (- : 0). The data show the 95% confidential interval.BMC Cancer 2009, 9:270 http://www.biomedcentral.com/1471-2407/9/270
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Spearman rank correlation coefficient relationship between serum concentrations of hepcidin-25, IL-6, and CRP Figure 2
Spearman rank correlation coefficient relationship between serum concentrations of hepcidin-25, IL-6, and 
CRP.BMC Cancer 2009, 9:270 http://www.biomedcentral.com/1471-2407/9/270
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and metastasis [25]. It has been reported that IL-6 is pro-
duced by most RCCs and it is assumed to be an autocrine
growth factor [26,27]. These findings suggest that the
serum IL-6 and CRP levels are associated with tumor
aggressiveness, so that elevation of IL-6 and CRP might
reflect the poor general condition of a patient. Motzer et
al. [28] identified five prognostic factors (Karnofsky per-
formance status, time from diagnosis of RCC to treatment,
serum lactate dehydrogenese, corrected serum calcium,
and hemoglobin) that were correlated with overall sur-
vival in patients who had metastatic RCC and were receiv-
ing systemic therapy, and this is known as the Memorial
Sloan-Kettering Cancer Center (MSKCC) classification.
The prognosis of our patients was consistent with the
MSKCC model. In the present study, patients from the
unfavorable risk group according to the MSKCC classifica-
tion had higher serum levels of IL-6, CRP, and hepcidin-
25 (data not shown). Recently, Ganz et al. reported that
serum hepcidin levels were increased in patients who had
inflammation and an elevated serum CRP level, multiple
myeloma, or chronic kidney disease, indicating that hep-
cidin is influenced by physiologic, pathologic, and genetic
factors, and that it provides useful information about the
etiology of iron disorders [29]. At present, it remains
unclear how elevation of serum hepcidin-25 reflects and/
or is involved in the progression of RCC, but our observa-
tions showed that the serum hepcdin-25 level was corre-
lated with the levels of IL-6 and CRP and that elevation of
all three factors was associated with metastasis of RCC.
Since there was no relationship between the serum hepci-
din-25 level and tumor expression of hepcidin mRNA in
this study, the origin of circulating hepcidin-25 might not
Hepcidin mRNAs in tumors Figure 3
Hepcidin mRNAs in tumors. A; In tumor vs. non-tumor tissues. B; Grade 1 to 3 tumors. C; In pT1–2 and pT3–4 tumors. C: 
In metastasis (+ : 1) and (- : 0). The data show the 95% confidential interval.BMC Cancer 2009, 9:270 http://www.biomedcentral.com/1471-2407/9/270
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be the cancer cells. Production of hepcidin-25 is induced
in the liver by IL-6 [19]. Kulaksiz et al. performed immu-
nohistochemistry of human, mouse, and rat kidneys,
which revealed similar patterns of hepcidin immunoreac-
tivity in the 3 species, including strong expression in the
cortical part of the thick ascending limb of the loop of
Henle and the collecting tubules, moderate expression in
the medullary part of the thick ascending limb and col-
lecting ducts, as well as in collecting ducts of the papilla,
and no expression in the proximal convoluted tubules
and the descending and ascending thin limbs [30]. Clear
cell RCC is thought to arise primarily from the proximal
convoluted tubules [31]. Therefore, our observation of
lower hepcidin mRNA expression in tumors tissues com-
pared with normal kidney tissue may reflect this origin.
Metastasis is the most common fatal complication of can-
cer and it involves dissemination of tumor cells to organs
distant from the primary lesion, so transport of tumor
cells through the body fluids is required [32]. The present
study showed that increased hepcidin mRNA expression
by RCC was associated with metastasis and survival in
patients. The meaning of local hepcidin expression
remains unclear. However our findings imply the altera-
tion to metastatic state with motility from steady state for
proliferation. Cell characteristics in cancer affected during
Epithelial-mesenchymal transition resulting in altered
cell-cell and cell-matrix interactions, cell motility and
invasiveness [33]. Iron metabolism may be different in
the state of migration from proliferation and it may affect
during hepcidin expression. Moreover, angiogenesis is
required for tumor metastasis and progression, and thus
represents a rational target for therapeutic intervention
[34]. HIF-1 is a key regulator of tumor angiogenesis [35].
After oncogenic transformation, HIF-1 protein is stabi-
lized and translocated into the nucleus where it regulates
the expression of various genes, including the key ang-
iogenic growth factor VEGF. In the majority of sporadic
clear cell RCCs, inactivation of the VHL tumor suppressor
gene is observed, and genetic or epigenetic silencing of
this gene may induce overexpression of HIF-1 [6]. Because
clear cell RCC is a vascular tumor that shows upregulation
of VEGF expression and metastasizes early via the hema-
togenous route, its prognosis is unfavorable [36]. There-
fore, HIF-1 is an attractive target for the development of
new anticancer therapies [37]. Iron is required as a cofac-
tor for the catalytic activity of HPHs [6], and is also a piv-
otal nutrient for cell growth and cell cycle regulation [7].
Furthermore, it has been reported that iron is more abun-
dant in RCC tissues than in non-tumor tissues [8].
Although we did not examine tumor and non-tumor tis-
sue iron levels, hepcidin mRNA expression was higher in
the RCCs with metastasis than in those without metasta-
sis, indicating that an increase of hepcidin mRNA expres-
sion might be associated with elevation of the iron
content in tumor cells.
While the origin of hepcidin-25 and hepcidin mRNA in
hepatocytes remains elusive, expression of hepcidin
mRNA in surgical specimens of hepatocellular carcinoma
(HCC) was lower than in non-tumorous liver tissue and
was not correlated with the serum hepcidin-25 level, as
was also found in the current study of RCC [11]. Moreo-
ver, hepcidin mRNA expression was not related to the his-
tological grade, vascular invasion, or recurrence of HCC
[11]. Hepcidin mRNA expression was detected in 10 out
of 34 surgical specimens from patients with colorectal
cancer, but was not detected in the majority of matched
non-tumorous tissues [12]. It has been reported that an
increase of colonocyte iron levels can lead to upregulation
of Wnt signalling, which has been shown to have a crucial
Survival curve based on the median values of mRNA expres- sion of hepcidin in tumors, the cases were divided into two  groups at this levels – high and low expression Figure 4
Survival curve based on the median values of mRNA 
expression of hepcidin in tumors, the cases were 
divided into two groups at this levels – high and low 
expression.BMC Cancer 2009, 9:270 http://www.biomedcentral.com/1471-2407/9/270
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role in colorectal carcinogenesis [38,39], indicating that
hepcidin might have a pro-oncogenic role by internaliza-
tion and degradation of the cellular iron export protein
ferroportin. Taken together, these findings suggest that
hepcidin might have differing roles in different cancers,
but an increase of iron based on increased hepcidin
mRNA expression in tumor cells might be necessary for
the metastasis of RCC. In the future, we should examine
whether hepcidin is involved in the VHL-HIF1-VEGF sig-
naling pathway and in the internalization and degrada-
tion of ferroportin in RCC.
As described above, hepcidin regulates the plasma iron
level by internalization and degradation of ferroportin in
enterocytes, hepatocytes, and macrophages [9,10]. In
addition, the hepcidin level increases in response to infec-
tion and it is an acute phase reactant induced by inflam-
mation that shows antimicrobial activity [9,10].
Therefore, an increase of the serum hepcidin-25 level in
patients with metastatic RCC might prevent tumor cells
from utilizing iron by upregulating tumor cell hepcidin as
an anticancer mechanism, as well as showing antimicro-
bial activity if infection occures. It is likely that hepcidin
plays multiple roles; e.g., hepcidin mRNA acts locally
within tumors and promotes their metastatic poteintial,
while hepcidin-25 also acts systemically to alleviate the
tumor burden in response to the progression of RCC.
Our study included a relatively small number of patients
and the follow-up period was too short to draw definite
conclusions regarding the possible relationship between
the serum hepcidin-25 level or tumor hepcidin mRNA
expression and the prognosis of RCC. However, our find-
ings suggested that serum hepcidin-25 may be an indica-
tor of metastasis and that an increase of hepcidin mRNA
expression in RCC may be associated with metastatic
potential. Accordingly, serum hepcidin-25 may be a use-
ful prognostic indicator and there is a potential role of
hepcidin in the metastasis of RCC. In the future, we
should study hepcidin protein expression to strengthen
our data about its role and carcinogenesis in metastasis.
We should also define the downstream targets of hepcidin
and study the expression or activity of such targets using
cultured tumor cell lines or tissue samples.
Conclusion
This study showed that an elevated serum hepcidin-25
level is indicative of metastatic disease, while over expres-
Table 1: Cox regression analysis for various potential prognostic factors in survival
Overall survival in 53 clear cell renal cell carcinomas
Variable Unfavorable/favorable characteristics No. of Patients Analysis Relative risk 95% confidential interval P value
Univariate (U) 18.529 5.287 – 27.819 < 0.0001
Karnofsky PS < 80%/> 80% 5/48
Multivariate (M) 24.718 2.793 – 11.729 0.0029
U 35.194 4.359 – 284.127 0.0008
Grade 4/3/2/1 0/15/30/8
M 85.943 4.123 – 1791.603 0.004
U 10.667 1.349 – 84.339 0.0248
pT 4.3/2.1 15/38
M 6.512 0.448 – 94.642 0.17
U 5.585 1.558 – 20.017 0.0083
Metastasis M1/M0 18/35
M 3.188 0.622 – 11.612 0.1273
U 4.177 1.105 – 15.784 0.0351
Hepcidin mRNA high/low 25/28
M 5.824 0.846 – 40.092 0.0734BMC Cancer 2009, 9:270 http://www.biomedcentral.com/1471-2407/9/270
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sion of hepcidin mRNA in tumor tissue is associated with
the metastatic potential of RCC.
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